DE69434316D1 - Verfahren zur Herstellung von trisubstituierten Imidazolen mit vielen therapeutischen Eigenschaften - Google Patents
Verfahren zur Herstellung von trisubstituierten Imidazolen mit vielen therapeutischen EigenschaftenInfo
- Publication number
- DE69434316D1 DE69434316D1 DE69434316T DE69434316T DE69434316D1 DE 69434316 D1 DE69434316 D1 DE 69434316D1 DE 69434316 T DE69434316 T DE 69434316T DE 69434316 T DE69434316 T DE 69434316T DE 69434316 D1 DE69434316 D1 DE 69434316D1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- therapeutic properties
- many therapeutic
- trisubstituted imidazoles
- trisubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9273393A | 1993-07-16 | 1993-07-16 | |
US92733 | 1993-07-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69434316D1 true DE69434316D1 (de) | 2005-04-28 |
DE69434316T2 DE69434316T2 (de) | 2006-03-09 |
Family
ID=22234840
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434316T Expired - Fee Related DE69434316T2 (de) | 1993-07-16 | 1994-07-15 | Verfahren zur Herstellung von trisubstituierten Imidazolverbindungen mit mehreren therapeutischen Eigenschaften |
DE69432463T Expired - Fee Related DE69432463T2 (de) | 1993-07-16 | 1994-07-15 | Trisubstituierte imidazole mit vielen therapeutischen eigenschaften |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69432463T Expired - Fee Related DE69432463T2 (de) | 1993-07-16 | 1994-07-15 | Trisubstituierte imidazole mit vielen therapeutischen eigenschaften |
Country Status (31)
Country | Link |
---|---|
EP (5) | EP0708768B1 (de) |
JP (4) | JPH09500137A (de) |
CN (2) | CN1050126C (de) |
AP (1) | AP484A (de) |
AT (2) | ATE291576T1 (de) |
AU (1) | AU694130C (de) |
BR (2) | BR9407079A (de) |
CA (1) | CA2167311A1 (de) |
CZ (1) | CZ11996A3 (de) |
DE (2) | DE69434316T2 (de) |
DK (1) | DK0708768T3 (de) |
DZ (1) | DZ1798A1 (de) |
ES (2) | ES2197167T3 (de) |
FI (1) | FI960177A (de) |
HK (4) | HK1049658A1 (de) |
HU (1) | HUT75313A (de) |
IL (2) | IL110296A (de) |
MA (1) | MA23270A1 (de) |
MY (1) | MY116478A (de) |
NO (4) | NO316881B1 (de) |
NZ (2) | NZ269457A (de) |
PL (4) | PL181723B1 (de) |
PT (1) | PT708768E (de) |
RU (1) | RU2140918C1 (de) |
SG (1) | SG52368A1 (de) |
SI (1) | SI0708768T1 (de) |
SK (1) | SK282342B6 (de) |
TW (1) | TW330934B (de) |
UA (1) | UA63875C2 (de) |
WO (1) | WO1995002591A1 (de) |
ZA (1) | ZA945193B (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3857751A (en) * | 1971-11-15 | 1974-12-31 | Tufdura Ltd | Composite sheet capable of withstanding impingement by particulate materials |
US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
US5840746A (en) * | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
US5670527A (en) * | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US6613789B2 (en) | 1994-07-28 | 2003-09-02 | G. D. Searle & Co. | Heterocyclo-substituted imidazoles for the treatment of inflammation |
PL321292A1 (en) * | 1995-01-12 | 1997-11-24 | Smithkline Beecham Corp | Novel xchemical compounds |
GB9500580D0 (en) * | 1995-01-12 | 1995-03-01 | Merck Sharp & Dohme | Therapeutic agents |
JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US6369068B1 (en) | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US6083949A (en) * | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
ZA9610687B (en) | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
AP9700912A0 (en) * | 1996-01-11 | 1997-01-31 | Smithkline Beecham Corp | Novel cycloalkyl substituted imidazoles |
US5756499A (en) * | 1996-01-11 | 1998-05-26 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
EP0883402A4 (de) * | 1996-01-11 | 1999-08-11 | Smithkline Beecham Corp | Neue cycloalkyl substituierte imidazole |
EP1005343A1 (de) * | 1996-03-08 | 2000-06-07 | Smithkline Beecham Corporation | Verwendung von csaids als inhibitoren der angiogenese |
JP2000507558A (ja) * | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Cns損傷についての新規な治療 |
DE69733135T2 (de) * | 1996-06-10 | 2006-03-02 | Merck & Co., Inc. | Substituierte imidazole mit cytokinin-inhibirender wirkung |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6608060B1 (en) | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5929076A (en) * | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
CA2294057A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
EP0994870A4 (de) | 1997-06-19 | 2002-10-23 | Smithkline Beecham | Neue,durch einen aryloxyrest substituierte imidazolverbindungen |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
CA2295762A1 (en) | 1997-07-02 | 1999-01-14 | Ravi Shanker Garigipati | Novel cycloalkyl substituted imidazoles |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
US6562832B1 (en) | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6489325B1 (en) | 1998-07-01 | 2002-12-03 | Smithkline Beecham Corporation | Substituted imidazole compounds |
WO1999017776A1 (en) | 1997-10-08 | 1999-04-15 | Smithkline Beecham Corporation | Novel cycloalkenyl substituted compounds |
AU9449398A (en) * | 1997-10-10 | 1999-05-03 | Imperial College Innovations Ltd. | Use of csaidtm compounds for the management of uterine contractions |
JP3337992B2 (ja) * | 1997-11-04 | 2002-10-28 | ファイザー製薬株式会社 | 5−置換ピコリン酸化合物及びその製造方法 |
AR017219A1 (es) | 1997-12-19 | 2001-08-22 | Smithkline Beecham Corp | Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento |
GB9809869D0 (en) * | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
AU760527C (en) | 1998-05-22 | 2004-05-06 | Smithkline Beecham Corporation | Novel 2-alkyl substituted imidazole compounds |
US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
AU4273099A (en) | 1998-06-24 | 2000-01-10 | Medical Research Council | Polypeptides, polynucleotides and uses thereof |
AU4395399A (en) * | 1998-07-02 | 2000-01-24 | Sankyo Company Limited | Five-membered heteroaryl compounds |
US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
CA2341370A1 (en) * | 1998-08-20 | 2000-03-02 | Smithkline Beecham Corporation | Novel substituted triazole compounds |
ATE258055T1 (de) | 1998-11-04 | 2004-02-15 | Smithkline Beecham Corp | Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine |
US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP2298311B1 (de) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer |
US7122666B2 (en) | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
WO2001038313A1 (en) | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
EP1235814B1 (de) | 1999-11-23 | 2004-11-03 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN |
US7053098B1 (en) | 1999-11-23 | 2006-05-30 | Smithkline Beecham Corporation | 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
US6627647B1 (en) | 2000-03-23 | 2003-09-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents |
FR2823747B1 (fr) * | 2001-04-24 | 2003-05-23 | Oreal | Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires |
FR2823751B1 (fr) * | 2001-04-24 | 2003-05-23 | Oreal | Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires |
WO2002094267A1 (fr) * | 2001-05-24 | 2002-11-28 | Sankyo Company, Limited | Preparation pharmaceutique pour prevenir ou traiter l'arthrite |
WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
DK1580188T3 (da) | 2002-02-11 | 2012-02-06 | Bayer Healthcare Llc | Forbindelser af arylurea som kinaseinhibitorer |
RU2217196C2 (ru) * | 2002-02-28 | 2003-11-27 | Небольсин Владимир Евгеньевич | Способ индукции дифференцировки клеток |
CN101597262A (zh) * | 2002-03-05 | 2009-12-09 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
ATE479683T1 (de) | 2002-11-05 | 2010-09-15 | Glaxo Group Ltd | Antibakterielle mittel |
EP1636585B2 (de) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-harnstoffe mit kinasehemmender wirkung |
ME00294B (me) | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti |
KR101296884B1 (ko) * | 2005-03-11 | 2013-08-14 | 젠야쿠코교가부시키가이샤 | 활성 성분으로서 헤테로시클릭 화합물을 포함하는 면역억제제 및 항암제 |
EP2470510B1 (de) | 2009-09-30 | 2014-05-14 | TransTech Pharma, LLC | Substituierte imidazol-derivate für die behandlung von alzheimers krankheit. |
WO2011051858A1 (en) | 2009-10-28 | 2011-05-05 | Pfizer Inc. | Imidazole derivatives as casein kinase inhibitors |
CN104387301B (zh) * | 2014-11-11 | 2016-05-04 | 常州大学 | 一种2-氟-4-甲基苯磺酰甲基异腈的合成方法 |
CN113350352A (zh) | 2015-03-23 | 2021-09-07 | 墨尔本大学 | 呼吸性疾病的治疗 |
CN110753688A (zh) * | 2017-05-03 | 2020-02-04 | 墨尔本大学 | 用于治疗呼吸***疾病的化合物 |
CN110531023B (zh) * | 2019-10-08 | 2024-06-14 | 安徽理工大学 | 一种薄层色谱分析仪 |
CN114112812B (zh) * | 2021-10-29 | 2024-05-24 | 华北电力大学 | 相变颗粒测试装置、固-液相变机理可视化实验台及方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) * | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
US3929807A (en) * | 1971-05-10 | 1975-12-30 | Ciba Geigy Corp | 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles |
AU9169991A (en) * | 1990-12-13 | 1992-07-08 | Smithkline Beecham Corporation | Novel csaids |
WO1992010190A1 (en) * | 1990-12-13 | 1992-06-25 | Smithkline Beecham Corporation | Novel csaids |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
-
1994
- 1994-07-12 IL IL11029694A patent/IL110296A/xx not_active IP Right Cessation
- 1994-07-13 AP APAP/P/1994/000654A patent/AP484A/en active
- 1994-07-13 DZ DZ940081A patent/DZ1798A1/fr active
- 1994-07-14 MY MYPI94001844A patent/MY116478A/en unknown
- 1994-07-14 MA MA23584A patent/MA23270A1/fr unknown
- 1994-07-15 EP EP94923503A patent/EP0708768B1/de not_active Expired - Lifetime
- 1994-07-15 AT AT02079534T patent/ATE291576T1/de not_active IP Right Cessation
- 1994-07-15 ES ES94923503T patent/ES2197167T3/es not_active Expired - Lifetime
- 1994-07-15 RU RU96103386/04A patent/RU2140918C1/ru not_active IP Right Cessation
- 1994-07-15 AT AT94923503T patent/ATE236896T1/de not_active IP Right Cessation
- 1994-07-15 NZ NZ269457A patent/NZ269457A/en unknown
- 1994-07-15 PL PL94332405A patent/PL181723B1/pl unknown
- 1994-07-15 PL PL94312614A patent/PL181705B1/pl unknown
- 1994-07-15 SI SI9430449T patent/SI0708768T1/xx unknown
- 1994-07-15 PL PL94332408A patent/PL181721B1/pl unknown
- 1994-07-15 HU HU9503855A patent/HUT75313A/hu unknown
- 1994-07-15 EP EP02079534A patent/EP1291346B1/de not_active Expired - Lifetime
- 1994-07-15 CN CN94193161A patent/CN1050126C/zh not_active Expired - Fee Related
- 1994-07-15 BR BR9407079A patent/BR9407079A/pt not_active Application Discontinuation
- 1994-07-15 UA UA96010110A patent/UA63875C2/uk unknown
- 1994-07-15 JP JP7504744A patent/JPH09500137A/ja active Pending
- 1994-07-15 CA CA002167311A patent/CA2167311A1/en not_active Abandoned
- 1994-07-15 PL PL94332406A patent/PL181694B1/pl unknown
- 1994-07-15 ZA ZA945193A patent/ZA945193B/xx unknown
- 1994-07-15 DE DE69434316T patent/DE69434316T2/de not_active Expired - Fee Related
- 1994-07-15 CZ CZ96119A patent/CZ11996A3/cs unknown
- 1994-07-15 WO PCT/US1994/007969 patent/WO1995002591A1/en not_active Application Discontinuation
- 1994-07-15 EP EP02076582A patent/EP1227092A3/de not_active Withdrawn
- 1994-07-15 PT PT94923503T patent/PT708768E/pt unknown
- 1994-07-15 ES ES02079534T patent/ES2237650T3/es not_active Expired - Lifetime
- 1994-07-15 EP EP02076580A patent/EP1227091A3/de not_active Withdrawn
- 1994-07-15 AU AU73354/94A patent/AU694130C/en not_active Ceased
- 1994-07-15 NZ NZ329994A patent/NZ329994A/xx unknown
- 1994-07-15 SK SK47-96A patent/SK282342B6/sk unknown
- 1994-07-15 DE DE69432463T patent/DE69432463T2/de not_active Expired - Fee Related
- 1994-07-15 SG SG1996003561A patent/SG52368A1/en unknown
- 1994-07-15 DK DK94923503T patent/DK0708768T3/da active
- 1994-07-15 EP EP02076581A patent/EP1229035A1/de not_active Withdrawn
- 1994-10-04 TW TW083109192A patent/TW330934B/zh active
-
1996
- 1996-01-15 NO NO960173A patent/NO316881B1/no not_active IP Right Cessation
- 1996-01-15 FI FI960177A patent/FI960177A/fi unknown
-
1997
- 1997-05-13 BR BR1100546-7A patent/BR1100546A/pt active IP Right Grant
-
1998
- 1998-05-04 IL IL12431898A patent/IL124318A0/xx unknown
- 1998-06-17 CN CN98115012A patent/CN1218801A/zh active Pending
- 1998-12-16 HK HK03100349.5A patent/HK1049658A1/zh unknown
- 1998-12-16 HK HK03100350.1A patent/HK1049659A1/zh unknown
- 1998-12-16 HK HK98113635A patent/HK1012392A1/xx not_active IP Right Cessation
- 1998-12-16 HK HK03100345.9A patent/HK1049657A1/zh unknown
-
2001
- 2001-02-19 NO NO20010839A patent/NO20010839D0/no not_active Application Discontinuation
- 2001-02-19 NO NO20010838A patent/NO20010838D0/no not_active Application Discontinuation
- 2001-02-19 NO NO20010837A patent/NO20010837D0/no not_active Application Discontinuation
-
2003
- 2003-12-10 JP JP2003412020A patent/JP2004083600A/ja active Pending
- 2003-12-10 JP JP2003412024A patent/JP2004149541A/ja active Pending
- 2003-12-10 JP JP2003412029A patent/JP2004099622A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434316D1 (de) | Verfahren zur Herstellung von trisubstituierten Imidazolen mit vielen therapeutischen Eigenschaften | |
DE59505881D1 (de) | Verfahren zur Herstellung von Xerogelen | |
DE69406158D1 (de) | Verfahren zur Herstellung von Olefinen mit endständigen Doppelbindungen | |
DE69416236D1 (de) | Verfahren zur Herstellung von Isocyanatoorganosilanen | |
DE69426173D1 (de) | Verfahren zur Herstellung von beta-Cyanoalkylsilanen | |
DE69424446D1 (de) | Verfahren zur Herstellung von Alkylsulfinylbenzamiden | |
DE69432649D1 (de) | Verfahren zur Herstellung von 1-Halogen-1-jodethan | |
DE59303220D1 (de) | Verfahren zur Herstellung von 1-Fluorcyclopropyl-methyl-keton | |
DE69403042D1 (de) | Verfahren zur Herstellung von Alkylcyclopentadienen | |
DE59407416D1 (de) | Verfahren zur Herstellung von N-Alkenylpyrrolidonen | |
DE69314899D1 (de) | Verfahren zur Herstellung von Polyaminoborazinen | |
DE59401893D1 (de) | Verfahren zur Herstellung von Trifluormethylanilinen | |
DE59401525D1 (de) | Verfahren zur Herstellung von Acetoacetarylamiden | |
DE69417526D1 (de) | Verfahren zur Herstellung von cis-1-Aminoindan-2-ol | |
DE69306099D1 (de) | Verfahren zur Herstellung von Monoalkenylbenzolen | |
DE69315297D1 (de) | Verfahren zur Herstellung von Omega-Alkenylchlorsilanen | |
DE59402596D1 (de) | Verfahren zur Herstellung von 5-Acetoacetylaminobenzimidazolon-2 | |
DE69303057D1 (de) | Verfahren zur Herstellung von 3-Cyano-6-hydroxypyridin | |
DE59403834D1 (de) | Verfahren zur Herstellung von m-Chloraromaten | |
DE69315317D1 (de) | Verfahren zur Herstellung von beta-Cyanoalkylsilanen | |
DE59405751D1 (de) | Verfahren zur Herstellung von Aminopropionitrilen | |
DE69404103D1 (de) | Verfahren zur Herstellung von Dibenzylaminen | |
DE69318765D1 (de) | Verfahren zur Herstellung von Hydridoorganooxysilanen | |
DE69321661D1 (de) | Verfahren zur Herstellung von Triorganomonohalogensilan | |
DE59407425D1 (de) | Verfahren zur Herstellung von Fluornitrobenzolen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |